skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: A syndrome of female pseudohermaphrodism, hypergonadotropic hypogonadism, and multicystic ovaries associated with missense mutations in the gene encoding aromatase (P450arom)

Journal Article · · Journal of Clinical Endocrinology and Metabolism
;  [1]; ; ;  [2]
  1. Univ. of California, San Francisco, CA (United States)
  2. Univ. of Texas Southwestern Medical Center, Dallas, TX (United States)

The authors report the features of a new syndrome of aromatase deficiency due to molecular defects in the CYP19 (P450arom) gene in a 46,XX female. At birth, the patient presented with a nonadrenal form of female pseudohermaphrodism. At 17 months of age, laparotomy revealed normal female internal genital structures; the histological appearance of the ovaries was normal. FSH concentrations were markedly elevated at 9.4 ng/mL LER 869, and estrone and estradiol levels were undetectable (<37 pmol/L). By 14 yr of age, she had failed to exhibit breast development. The clitoris has enlarged to 4 x 2 cm, and pubic hair was Tanner stage IV. The plasma concentration of testosterone was elevated at 3294 pmol/L, as was androstenedione at 9951 pmol/L. Plasma estradiol levels were below 37 pmol/L. ACTH and dexamethasone tests indicated a nonadrenal source of testosterone and androstenedione. Plasma gonadotropin levels were in the castrate range. Pelvic sonography and magnetic resonance imaging showed multiple 4- to 6-cm ovarian cysts bilaterally. Despite increased circulating androgens and clitoral growth, the bone age was 10 yr at chronologic age 14 2/12 yr. Estrogen replacement therapy resulted in a growth spurt, breast development, menarche, suppression of gonadotropin levels, and resolution of the cysts. The clinical findings suggested the diagnosis of P450arom deficiency. Analyses of genomic DNA from ovarian fibroblasts demonstrated two single base changes in the coding region of the P450arom gene, one at 1303 basepairs (C-T), R435C, and the other at 1310 basepairs (G-A), C437Y, in exon 10. The molecular genetic studies indicate that the patient is a compound heterozygote for these mutations. Expression of these mutations showed that the R435C mutation had 1.1% the activity of the wild-type P450arom enzyme, whereas the C437Y mutation demonstrated no activity. 32 refs., 6 figs., 2 tabs.

OSTI ID:
54467
Journal Information:
Journal of Clinical Endocrinology and Metabolism, Vol. 78, Issue 6; Other Information: PBD: Jun 1994
Country of Publication:
United States
Language:
English

Similar Records

Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens
Journal Article · Fri Dec 01 00:00:00 EST 1995 · Journal of Clinical Endocrinology and Metabolism · OSTI ID:54467

Evaluation of a bioluminescent mouse model expressing aromatase PII-promoter-controlled luciferase as a tool for the study of endocrine disrupting chemicals
Journal Article · Mon Nov 15 00:00:00 EST 2010 · Toxicology and Applied Pharmacology · OSTI ID:54467

Synthesis and PET studies of [11C-cyano]letrozole (Femara), an aromatase inhibitor drug
Journal Article · Mon Nov 10 00:00:00 EST 2008 · Nuclear Medicine and Biology · OSTI ID:54467